FDA Approves Onswik (Insulin Efsitora Alfa-Gobe) — the First Once-Weekly Basal Insulin for Type 2 Diabetes in the U.S.

FDA Approves Onswik (Insulin Efsitora Alfa-Gobe) — the First Once-Weekly Basal Insulin for Type 2 Diabetes in the U.S.

September 24, 2026. The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, "as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes" — the first once-weekly basal insulin cleared in the U.S., and Lilly's fourth global regulatory clearance for the agent after the EMA, Mexico's COFEPRIS, and Japan's PMDA (Patient Care Online, citing Lilly's Sept 24 press release).

The approval rests on the QWINT Phase 3 program — four multinational, randomized, open-label, treat-to-target trials enrolling more than 3,400 adults with type 2 diabetes (2022–2025). In each trial the primary endpoint — non-inferior HbA1c reduction at week 26 or 52 — was met versus once-daily insulin glargine U-100 or insulin degludec U-100, "the overall safety profile of efsitora was reported to be similar to that of the comparator daily basal insulins across all four trials."

The commercial pitch is injection burden: Lilly says the approval "is anticipated to reduce the annual injection burden from approximately 365 doses with once-daily basal insulin to 52 doses per year¹ — a reduction of more than 300 injections annually" (Kenneth Custer, president of Lilly Cardiometabolic Health: "delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes").

Key label limits: not approved for type 1 diabetes (severe hypoglycemia risk); supplied as U-500 and U-1,000 prefilled KwikPens with maximum single doses of 400 and 800 units — dosing that "differs substantively from other injectable insulin products, necessitating careful patient education to prevent dosing errors." Availability in the U.S. is expected "within the coming months."

Competitive context: Lilly reaches the U.S. market first with a weekly basal insulin — Novo Nordisk's once-weekly basal insulin candidate (insulin icodec) was rejected by the FDA in July, per Pharmaphorum, leaving Lilly alone in the category.